Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies.

Qayyum A, Zai CC, Hirata Y, Tiwari AK, Cheema S, Nowrouzi B, Beitchman JH, Kennedy JL.

Curr Neuropharmacol. 2015;13(6):802-14. Review.

2.

Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder.

Tourian L, LeBoeuf A, Breton JJ, Cohen D, Gignac M, Labelle R, Guile JM, Renaud J.

J Can Acad Child Adolesc Psychiatry. 2015 Winter;24(1):41-54. Epub 2015 Mar 4.

3.

A comparison of risperidone and buspirone for treatment of behavior disorders in children with phenylketonuria.

Fayyazi A, Salari E, Khajeh A, Gajarpour A.

Iran J Child Neurol. 2014 Fall;8(4):33-8.

4.

Disruptive mood dysregulation disorder: a new diagnostic approach to chronic irritability in youth.

Roy AK, Lopes V, Klein RG.

Am J Psychiatry. 2014 Sep;171(9):918-24. doi: 10.1176/appi.ajp.2014.13101301. Review.

6.

What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?

Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK, Rundberg-Rivera EV, Li X, Kipp H, Schneider J, Butter EM, Baker J, Sprafkin J, Rice RR Jr, Bangalore SS, Farmer CA, Austin AB, Buchan-Page KA, Brown NV, Hurt EA, Grondhuis SN, Findling RL.

J Am Acad Child Adolesc Psychiatry. 2014 Jan;53(1):47-60.e1. doi: 10.1016/j.jaac.2013.09.022. Epub 2013 Nov 18.

7.

Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.

Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh PJ, Arango C, K├Âlch M, Coghill D, Flamarique I, Penzol MJ, Wan M, Murray M, Wong IC, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert JM, Vicari S, Carucci S, Dittmann RW, Buitelaar JK; PERS Consortium..

Eur Child Adolesc Psychiatry. 2014 Dec;23(12):1149-60. doi: 10.1007/s00787-013-0498-3. Epub 2013 Dec 15.

8.

Frequency, characteristics and management of adolescent inpatient aggression.

Baeza I, Correll CU, Saito E, Amanbekova D, Ramani M, Kapoor S, Chekuri R, De Hert M, Carbon M.

J Child Adolesc Psychopharmacol. 2013 May;23(4):271-81. doi: 10.1089/cap.2012.0116. Epub 2013 May 6.

9.

Differentiating bipolar disorder-not otherwise specified and severe mood dysregulation.

Towbin K, Axelson D, Leibenluft E, Birmaher B.

J Am Acad Child Adolesc Psychiatry. 2013 May;52(5):466-81. doi: 10.1016/j.jaac.2013.02.006. Epub 2013 Apr 4. Review.

10.

Effects of aromatase inhibition and androgen activity on serotonin and behavior in male macaques.

Bethea CL, Reddy AP, Robertson N, Coleman K.

Behav Neurosci. 2013 Jun;127(3):400-14. doi: 10.1037/a0032016. Epub 2013 Mar 18.

11.
12.

Update on the role of antipsychotics in the treatment of Tourette syndrome.

Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J.

Neuropsychiatr Dis Treat. 2012;8:95-104. doi: 10.2147/NDT.S12990. Epub 2012 Mar 12.

13.

Experts' recommendations for treating maladaptive aggression in youth.

Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, Jensen PS.

J Child Adolesc Psychopharmacol. 2011 Dec;21(6):505-15. doi: 10.1089/cap.2010.0128.

14.

Risperidone in the treatment of conduct disorder in preschool children without intellectual disability.

Ercan ES, Basay BK, Basay O, Durak S, Ozbaran B.

Child Adolesc Psychiatry Ment Health. 2011 Apr 13;5(1):10. doi: 10.1186/1753-2000-5-10.

15.

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group..

Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96. doi: 10.1007/s00787-011-0163-7. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.

16.

Neuroendocrine aspects of pediatric aggression: Can hormone measures be clinically useful?

Barzman DH, Patel A, Sonnier L, Strawn JR.

Neuropsychiatr Dis Treat. 2010 Oct 11;6:691-7. doi: 10.2147/NDT.S5832.

17.

Day treatment for disruptive behaviour disorders: can a short-term program be effective?

Jerrott S, Clark SE, Fearon I.

J Can Acad Child Adolesc Psychiatry. 2010 May;19(2):88-93.

18.

Gender-specific expression of the DRD4 gene on adolescent delinquency, anger and thrill seeking.

Dmitrieva J, Chen C, Greenberger E, Ogunseitan O, Ding YC.

Soc Cogn Affect Neurosci. 2011 Jan;6(1):82-9. doi: 10.1093/scan/nsq020. Epub 2010 Mar 4.

19.

Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.

Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V.

Am J Psychiatry. 2009 Dec;166(12):1392-401. doi: 10.1176/appi.ajp.2009.09020233. Epub 2009 Nov 2.

20.

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.

Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):563-73. doi: 10.1089/cap.2009.0051.

Supplemental Content

Support Center